UA140579U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

A method for predicting the development of osteoarthritis, including clinical examination, radiography. Additionally, in the patient's serum determine the polymorphism of genes methylenetetrahydrofolate reductase (MTHFR C677T), nitric oxide synthase (eNOS T786C), the content of endothelin, folic acid, interleukin 6 (IL-6), C-reactive protein (g) and protein homozygous carriers 677-TT, 786-CC and endothelin levels> 10 ng / ml, folic acid <6 ng / ml, IL-6> 10 ng / l, PSA> 6 mg / l, GAG> 28 μmol / l predict the development osteoarthritis.

Description

A useful model belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in the diagnosis of the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include radiography, examination of a biopsy of the synovial membrane, synovial fluid, a biopsy of cartilage (Okorokov

A.N. Diagnosis of diseases of internal organs. - M, 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that in the method of predicting the development of osteoarthritis, which includes a clinical examination and radiography, according to a useful model, the polymorphism of the genes methylenetetrahydrofolate reductase (MITNENV Сб677Т), nitric oxide synthase (еМмО5 17860), the content of endothelin, folic acid is determined in the patient's blood serum , interleukin b (IL-6), C-reactive protein (SRP), glycosaminoglycans (GAG). With homozygous carrier 677-Tt, 786-

SS, levels of endothelin 210 ng/ml, folic acid "6 ng/ml, IL-6 "10 ng/l, SRP "6 mg/l, GAG 528 μmol/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, X-rays are taken, the polymorphism of MTNEV C677T, eMmo5 T786C genes is determined, the content of endothelin, folic acid, IL-6, SRP, GAG is determined by the immunoenzymatic method. With homozygous carrier 677-1T, 786-SS, levels of endothelin 210 ng/ml, folic acid "6 ng/ml, IL-6 "10 ng/l, SRP "6 mg/l, GAG 528 μmol/l predict the development of osteoarthritis .

An example of using the method

Patient G., 68 years old, was hospitalized in the clinic due to pain syndrome of the left hip joint. Examined, X-ray taken. No signs of osteoarthritis were found. The polymorphism of MTNEV C677T and emo5 17860 genes was determined in blood serum. The content of endothelin, folic acid, IL-6, SRP, GAG was determined by immunoenzymatic method. A homozygous carrier of 677-TT and 786-SS was established, the levels of endothelin - 23 ng/ml, folic acid - 3.6 ng/ml, IL-6-25 ng/l, SRP - 17 mg/l, GAG - 48 μmol/ l. The development of osteoarthritis was diagnosed. After 11 months

X-rays showed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that in the patient's blood serum polymorphism of the genes methylenetetrahydrofolate reductase (MTNEV C677T), nitric oxide synthase (EMO5 1786С), the content of endothelin, folic acid, interleukin b (IL- 6), C-reactive protein (SRP), glycosaminoglycans (GAG) and with homozygous carrier 677-TT, 786-SS and levels of endothelin 210 ng/ml, folic acid "6 ng/ml, IL-6 210 ng/l, SRP "6 mg/l, GAG x"28 μmol/l predict the development of osteoarthritis.